Olivier Espitia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7574450/publications.pdf

Version: 2024-02-01

49 papers

1,049 citations

16 h-index 454955 30 g-index

74 all docs

74 docs citations

74 times ranked 1282 citing authors

#	Article	IF	CITATIONS
1	Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Revue De Medecine Interne, 2016, 37, 154-165.	1.0	152
2	Skin Patch, Polyneuropathy, and Paraproteinemia. American Journal of Medicine, 2012, 125, e1-e2.	1.5	93
3	Giant Cell Arteritis with or without Aortitis at Diagnosis. A Retrospective Study of 22 Patients with Longterm Followup. Journal of Rheumatology, 2012, 39, 2157-2162.	2.0	80
4	Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries. Scientific Reports, 2018, 8, 3940.	3.3	78
5	Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. Journal of Rheumatology, 2016, 43, 1547-1552.	2.0	56
6	Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. Autoimmunity Reviews, 2016, 15, 571-576.	5.8	55
7	Longâ€∓erm Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients. Journal of the American Heart Association, 2018, 7, e010677.	3.7	40
8	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212705.	0.9	38
9	Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. Journal of Autoimmunity, 2019, 103, 102283.	6.5	36
10	A STROBE cohort study of 755 deep and superficial upper-extremity vein thrombosis. Medicine (United) Tj ETQq0	0 0 0 rgBT 1.0	/Overlock 10
11	Sj \tilde{A} ¶gren's syndrome-associated myositis with germinal centre-like structures. Autoimmunity Reviews, 2017, 16, 154-158.	5.8	26
12	Implication of molecular vascular smooth muscle cell heterogeneity among arterial beds in arterial calcification. PLoS ONE, 2018, 13, e0191976.	2.5	25
13	Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event. Arthritis Research and Therapy, 2021, 23, 14.	3.5	25
14	Exercise-Induced Vasculitis: A Review with Illustrated Cases. American Journal of Clinical Dermatology, 2016, 17, 635-642.	6.7	23
15	Long-Term Outcome and Prognosis Factors of Isolated Aortitis. Circulation, 2020, 142, 92-94.	1.6	22
16	Large-vessel involvement is predictive of multiple relapses in giant cell arteritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110090.	2.7	18
17	Juvenile temporal arteritis: A clinicopathological multicentric experience. Autoimmunity Reviews, 2019, 18, 476-483.	5.8	16
18	A case of aortic and mitral valve involvement in granulomatosis with polyangiitis. Cardiovascular Pathology, 2014, 23, 363-365.	1.6	13

#	Article	IF	CITATIONS
19	Large-vessel vasculitis diagnosed between 50 and 60†years: Case-control study based on 183 cases and 183 controls aged over 60†years. Autoimmunity Reviews, 2019, 18, 714-720.	5.8	12
20	Comparative clinical prognosis of massive and nonâ€massive pulmonary embolism: A registryâ€based cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 408-416.	3.8	12
21	Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study. Clinical Rheumatology, 2019, 38, 1243-1249.	2.2	11
22	A strobe multicenter descriptive study of 55 infectious aortitis. Medicine (United States), 2020, 99, e22422.	1.0	11
23	Giant cell arteritis-related aortic dissection: A multicenter retrospective study. Seminars in Arthritis and Rheumatism, 2021, 51, 430-435.	3.4	11
24	Specific features to differentiate Giant cell arteritis aortitis from aortic atheroma using FDG-PET/CT. Scientific Reports, 2021, 11, 17389.	3.3	10
25	Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. European Journal of Cancer, 2022, 160, 134-139.	2.8	10
26	Livedo-like dermatitis and necrotic lesions after high-dose buprenorphine injections: a national French survey. British Journal of Dermatology, 2015, 172, 1412-1414.	1.5	9
27	Thrombin Generation Assay in Hospitalized Nonsurgical Patients. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 45-51.	1.7	7
28	Image Gallery: Nicolau syndrome after misuse of buprenorphine. British Journal of Dermatology, 2017, 176, e35-e35.	1.5	7
29	Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110069.	2.7	7
30	Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis. Arthritis Research and Therapy, 2021, 23, 143.	3.5	6
31	Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage. Platelets, 2017, 28, 518-520.	2.3	5
32	Giant cell arteritis-related aortitis with positive or negative temporal artery biopsy: a French multicentre study. Scandinavian Journal of Rheumatology, 2019, 48, 474-481.	1.1	5
33	Prevalence of post-thrombotic syndrome in a cohort of upper extremity vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 111-117.e3.	1.6	5
34	Short- and Mid-Term Outcomes of Endovascular Stenting for the Treatment of Post-Thrombotic Syndrome due to Iliofemoral and Caval Occlusive Disease: A Multi-Centric Study from the French Society of Diagnostic and Interventional Cardiovascular Imaging (SFICV). CardioVascular and Interventional Radiology, 2022, 45, 162-171.	2.0	5
35	Spectrum and Outcome of Noninfectious Aortitis. Journal of Rheumatology, 2021, 48, 1583-1588.	2.0	4
36	Colour Doppler ultrasound of temporal arteries for the diagnosis of giant cell arteritis: a multicentre deep learning study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 120-125.	0.8	4

#	Article	lF	CITATIONS
37	Impact of Femoral Ossification on Local and Systemic Cardiovascular Patients' Condition. Annals of Vascular Surgery, 2019, 60, 335-345.	0.9	3
38	Vascular Presentation and Outcomes of Patients With Giant Cell Arteritis and Isolated Symptomatic Limb Involvement. Journal of Clinical Rheumatology, 2020, 26, 248-254.	0.9	3
39	Predictive factors of venous recanalization in upper-extremity vein thrombosis. PLoS ONE, 2021, 16, e0251269.	2.5	3
40	Image Gallery: Bilateral juvenile temporal arteritis. British Journal of Dermatology, 2018, 179, e168-e168.	1.5	2
41	Women and Pregnancy in Thromboangiitis Obliterans. Journal of Vascular Research, 2021, 58, 1-3.	1.4	2
42	A rare case of worsening of Parkes-Weber syndrome with development of POEMS syndrome. British Journal of Haematology, 2016, 175, 558-558.	2.5	1
43	Scalp Necrosis in Giant Cell Arteritis. Mayo Clinic Proceedings, 2021, 96, 987-988.	3.0	1
44	Refinement of a modified simplified Pulmonary Embolism Severity Index for elderly patients with acute pulmonary embolism. International Journal of Cardiology, 2021, 335, 111-117.	1.7	1
45	Multiple concomitant arterial aneurysms in Behçet's disease. Vascular, 2022, , 170853812210766.	0.9	1
46	FRIO220â€Aortic involvement at onset impacts long term outcome in giant cell arteritis: A 12 years follow-up study. Annals of the Rheumatic Diseases, 2013, 71, 388.2-388.	0.9	0
47	SAT0351â€Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study OF34 Patients. Annals of the Rheumatic Diseases, 2016, 75, 794.1-794.	0.9	0
48	Effect of cannabis consumption on characteristics and evolution of thromboangitis obliterans. Vasa - European Journal of Vascular Medicine, 2021, 50, 1-5.	1.4	0
49	Case–Control Study on Exercise-Induced Vasculitis in Hikers. Angiology, 2022, , 000331972110657.	1.8	0